SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Skin Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 89 years
- Gender
- Both males and females
Description
The purpose of this study is to see whether a teledermatologist can correctly diagnose skin cancer with the same accuracy as an in-person dermatologist. Telemedicine allows health care professionals to remotely evaluate, diagnose, and treat patients (i.e. without seeing you in person). A dermatologi...
The purpose of this study is to see whether a teledermatologist can correctly diagnose skin cancer with the same accuracy as an in-person dermatologist. Telemedicine allows health care professionals to remotely evaluate, diagnose, and treat patients (i.e. without seeing you in person). A dermatologist who is not seeing the patient in person is called a teledermatologist. Currently, the standard of care, which means the accepted first choice of management, is an in-person evaluation. The telemedicine method that will use in this study is called 'store and forward'. This means the information will be sent to the teledermatologist after the patient leaves the clinic. The teledermatologist will use close-up photos and a device called Nevisense to make the diagnosis.
Tracking Information
- NCT #
- NCT04411810
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: David Polsky, MD, PhD NYU Langone Health